VEGF Receptor 2 antibody

GeneTex

VEGF Receptor 2 antibody

9

The antibody has the ability to neutralize the biological activity of recombinant mouse VEGF R2. It demonstates approximately 40% cross-reactivity with recombinant human VEGF R2, 2% cross-reactivty with recombinant mouse VEGF R1, and no cross-reactivity w

WB: 0.1-0.2 microg/ml. FACS: 3-10 microg/ml. IHC: 5-15 microg/ml. Neutralizing/Inhibition: 0.1-0.3 microg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

Flow Cytometry, Western Blot, ImmunoHistoChemistry, Neutralisation/Blocking

Research Use Only

Polyclonal

Unconjugated

Liquid

Kdr

kinase insert domain protein receptor

6130401C07; fetal liver kinase 1; Flk; Flk-; Flk1; Flk-1; kinase NYK; Krd-1; Ly73; orv; protein-tyrosine kinase receptor flk-1; soluble vascular endothelial growth factor receptor 2; sVEGFR-2; vascular endothelial growth factor receptor 2; vascular endothelial growth factor receptor-3; VEGF; VEGF receptor-2; VEGFR; VEGFR2; VEGFR-2

Goat

IgG

Vascular endothelial growth factors (VEGFs) are a family of closely related growth factors having a conserved pattern of eight cysteine residues and sharing common VEGF receptors. VEGFs stimulate the proliferation of endothelial cells, induce angiogenesis, and increase vascular permeability in both large and small vessels. The mitogenic activity of VEGFs appears to be mediated by specific VEGF receptors. Vascular Endothelial Growth Factor Receptor 2 (VEGF Receptor 2, KDR, Flk1) is one of the five receptor tyrosine kinases (RTKs) (VEGF Receptor 1/Flt1, VEGF Receptor 2/KDR/Flk1, VEGF Receptor 3/Flt4, tie1 and tek/tie2) whose expression is almost exclusively restricted to endothelial cells. These RTKs play central roles in vasculogenesis and angiogenesis. Tie1 and tek/tie2 are a class of RTKs containing two immunoglobulin-like domains, three EGF homology domains and three fibronectin type III domains in their extracellular regions. VEGF Receptor 1/Flt1, VEGF Receptor 2/KDR/Flk1, and VEGF Receptor 3/Flt4 are members of the class III subfamily of RTKs containing seven immunoglobulin-like repeats in their extracellular domains. VEGF Receptor 1 and VEGF Receptor 2 are both expressed in an endothelial cell-specific manner. They are detectable in virtually all tissues in adults and embryos. Monocytes express VEGF Receptor 1 and VEGF Receptor 2. VEGF Receptor 2 is also expressed in pancreatic duct cells, hematopoietic stem cells, megakaryocytes, specific tumor cell types such as malignant melanoma cells, and retinal progenitor cells. In the retina, two functional VEGF Receptor 2 forms are expressed as a result of alternative splicing. VEGF Receptor 2 is a key marker for pluripotent hematopoietic stem cells. VEGF Receptor 1 and VEGF Receptor 2 are closely related in their putative roles in angiogenesis. VEGF Receptor 2 is involved in commitment of endothelial-cell lineages and to cell proliferation, while VEGF Receptor 1 seems to be responsible for guiding endothelial cells into the proper spatial organization of the lumen-containing vessels. VEGF Receptor 1 binds both PIGF and VEGF with high affinity, whereas VEGF Receptor 2 binds VEGF with high affinity but does not bind PIGF. Recombinant soluble VEGF Receptor 2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

Mouse

-20°C or -80°C,2°C to 8°C

12352203